A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies
NCT02327169
Completed
The primary purpose of this study is to determine the safety profile and the maximum tolerated doses (MTDs)/ potential recommended phase 2 doses (RP2Ds) of the combination treatments of MLN2480 + MLN0128, MLN2480 + alisertib, MLN2480 + paclitaxel, MLN2480 + cetuximab, and MLN2480 + irinotecan in participants with advanced nonhematologic malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2020
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Nonhematologic Malignancies
Register for Updates
A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
NCT02117024
Terminated
Determine whether viagenpumatucel-L combined with low-dose cyclophosphamide prolongs survival in patients with NSCLC who failed 2 or 3 prior lines of therapy for incurable or metastatic disease compared with chemotherapy alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2020
Locations: Texas Oncology PA Texas Cancer Center, Abilene, Texas +1 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
NCT02383212
Completed
This is a phase 1, open-label, multicenter, ascending-dose escalation study of cemiplimab, alone and in combination with other anti-cancer therapies in patients with advanced malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2020
Locations: Mary Crowley Cancer Research Center - Medical City, Dallas, Texas +3 locations
Conditions: Advanced Cancer, Advanced Malignancies
Register for Updates
Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas
NCT01730586
Completed
The goal of this clinical research study is to learn if abraxane can help to control colorectal and/or small bowel cancer. The safety of this drug will also be studied. Abraxane is designed to block cancer cells from dividing, which may cause them to die.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2020
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Colorectal Cancer, Cancer of Gastrointestinal Tract
Register for Updates
TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
NCT00563784
Completed
The goal of this clinical research study is to find out if erlotinib given with chemotherapy and radiation therapy can help to control NSCLC. The safety of this combination treatment will also be studied. Researchers will also test the tissue from your earlier biopsy to measure the levels of epidermal growth factor receptor (EGFR). The purpose of EGFR testing is to learn about any link between various forms of EGFR and your response to treatment with erlotinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2019
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Non-Small Cell Lung Cancer, Lung Cancer
Register for Updates
Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer
NCT00093145
Completed
This trial will treat patients with advanced breast cancer with a new anti-cancer medicine used in combination with two existing anti-cancer medications: Albumin-bound paclitaxel (ABI-007), Carboplatin and Herceptin. Participants will be given the combination therapy on a weekly basis and may continue on therapy as long as their condition improves and drug toxicity is tolerated.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/13/2019
Locations: Southwest Regional Cancer Center, Austin, Texas
Conditions: Breast Cancer
Register for Updates
ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer
NCT00394082
Completed
The purpose of this study is to evaluate the safety and tolerability of weekly ABI-007 in combination with bevacizumab. The evaluation of progression-free survival of weekly ABI-007 in combination with bevacizumab for patients with previously untreated advanced/metastatic breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/13/2019
Locations: Not set, Bedford, Texas +5 locations
Conditions: Metastatic Breast Cancer
Register for Updates
Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
NCT00281528
Terminated
This is a multi-center, open-label, randomized Phase II study in previously untreated patients with metastatic breast cancer to evaluate the antitumor activity and safety of weekly dose-dense ABI-007 (Abraxane) compared to 2-weekly regimen vs the standard 3-weekly infusion. All patients will also receive concurrent bevacizumab.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/07/2019
Locations: TX Oncology, PA, Austin, Texas +1 locations
Conditions: Breast Neoplasms, Neoplasm Metastasis
Register for Updates
Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
NCT00394251
Completed
The primary objective of this study was to compare the safety of dose-dense ABI-007 (Abraxane) 260 mg/m\^2 or Taxol 175 mg/m\^2 given every 2 weeks following dose-dense Adriamycin plus Cytoxan (AC) chemotherapy. Bevacizumab was administered at 10 mg/kg every 2 weeks throughout chemotherapy, and then at 15 mg/kg every 3 weeks following chemotherapy.
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
11/07/2019
Locations: Not set, Austin, Texas +11 locations
Conditions: Breast Cancer
Register for Updates
Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer
NCT00398086
Completed
To determine the maximum tolerated dose and dose-limiting toxicity of Gemcitabine plus Albumin-bound paclitaxel (ABI-007) in patients with advanced metastatic pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/07/2019
Locations: South Texas Oncology & Hematology, San Antonio, Texas
Conditions: Metastatic Pancreatic Cancer
Register for Updates
Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
NCT00844649
Completed
Phase III Metastatic Pancreatic Cancer
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
11/07/2019
Locations: Medical City Dallas-US Oncology, Dallas, Texas +10 locations
Conditions: Metastatic Pancreatic Cancer
Register for Updates
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
NCT01478685
Completed
The purpose of the study is to evaluate the safety and to define the Maximal Tolerated Dose (MTD) or the Maximal Administered Dose (MAD) of oral azacitidine as a single agent and in combination with carboplatin (CBDCA) or paclitaxel protein bound particles (ABI-007,ABX) in subjects with relapsed or refractory solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/07/2019
Locations: South Texas Accelerated Research Therapeutics, San Antonio, Texas
Conditions: Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Tumor Virus Infections
Register for Updates